人 FBXW11 抗体对
01AB02603
F-box and WD repeat domain containing 11 (FBXW11), also known as beta-TrCP2, is the substrate-recognition subunit of the SCF (SKP1-CUL1-F-box) E3 ubiquitin ligase complex. It utilizes C-terminal WD40 repeats to recognize phosphorylated degrons on various target proteins, including beta-catenin, IkBa, and PER1/2. By mediating the ubiquitin-dependent proteolysis of these substrates, FBXW11 regulates critical signaling pathways such as Wnt, NF-kappaB, and the circadian clock. Clinically, FBXW11 is overexpressed in acute lymphoblastic leukemia (ALL), where it promotes leukemic cell proliferation and tumor formation by activating NF-kappaB and beta-catenin/TCF signaling. This suggests an oncogenic role for FBXW11 in hematologic malignancies and identifies it as a potential therapeutic target.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- FBXW11
- 基因别名
- BTRCP2; FBW1B; FBXW1B; KIAA0696
- 蛋白别名
- F-box and WD repeat domain containing 11; FBXW11
- UniProt
- Q9UKB1
- 物种
- Human
产品详情
- 靶点名称
- FBXW11
- 蛋白名称
- F-box and WD repeat domain containing 11
- 蛋白别名
- F-box/WD repeat-containing protein 11; F-box and WD repeats protein beta-TrCP2; F-box/WD repeat-containing protein 1B; Homologous to Slimb protein; HOS
- 靶点基因名
- FBXW11
- 基因别名
- BTRCP2; FBW1B; FBXW1B; KIAA0696
- UniProt
- Q9UKB1
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
F-box and WD repeat domain containing 11 (FBXW11), also known as beta-TrCP2, is the substrate-recognition subunit of the SCF (SKP1-CUL1-F-box) E3 ubiquitin ligase complex. It utilizes C-terminal WD40 repeats to recognize phosphorylated degrons on various target proteins, including beta-catenin, IkBa, and PER1/2. By mediating the ubiquitin-dependent proteolysis of these substrates, FBXW11 regulates critical signaling pathways such as Wnt, NF-kappaB, and the circadian clock. Clinically, FBXW11 is overexpressed in acute lymphoblastic leukemia (ALL), where it promotes leukemic cell proliferation and tumor formation by activating NF-kappaB and beta-catenin/TCF signaling. This suggests an oncogenic role for FBXW11 in hematologic malignancies and identifies it as a potential therapeutic target.